Earn points on every order · Free shipping on orders over $159 · New products in stock
← Back to Compound Library
Growth Hormone Axis

IGF-1 (STANDARD)

The growth signal that GH normally creates downstream. Injecting it directly skips a step. Tanks blood sugar, eat carbs with it.

Research referenceCommunity compiled
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

The growth signal that GH normally creates downstream. Injecting it directly skips a step. Tanks blood sugar, eat carbs with it.

What It Does

Standard insulin-like growth factor 1, the natural form with a 12–15 min half-life. Binds IGF-1 receptor (IGF-1R) on muscle cells to activate PI3K/AKT and MAPK/ERK pathways, promoting protein synthesis, satellite cell activation.

Reconstitution

Vial SizeBAC Water / SolventConcentration
1 mg+ 2.5 mL0.4 mg/mL
Interactive tool

Reconstitution Calculator

Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.

Calculated concentration—Enter both values above.
Optional conversion

Enter a target amount you already have and select the syringe capacity.

Calculated draw—Enter concentration inputs and a target amount.

Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.

Protocol

PhaseFrequencyAmountNotes
EntryPost-workout daily20–40 mcgStart here. Assess hypoglycemia response before increasing.
WorkingPost-workout daily60–80 mcgCommunity working dose. Have fast carbs available.
MaxPost-workout daily100 mcgUpper community range. Do not exceed without monitoring.
Off4 weeks–Receptor sensitivity reset.
Cycle & Timing

4–6 weeks on, 4 weeks off. Short cycles only.

Timing

With food, fast-acting carbs available; never fasted (hypoglycemia risk).

Population Considerations

Direct IGF-1 bypasses GH, so estrogen doesn’t soften it; same growth-signal caution: breast, ovarian, or uterine history. Men: Same growth-signal caution, prostate; watch PSA in men over Direct IGF-1 bypasses GH, so estrogen doesn’t soften it; same growth-signal caution: breast, ovarian, or uterine history. Men: Same growth-signal caution, prostate; watch PSA in men over ~40.

Handling & Stacking

Injection site
SubQ or IM directly into trained muscle for site-specific effect.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F, best used within ~10–14 days (structure-based estimate, no published data); potency fades before the 28- day sterility limit, so keep it cold and use it promptly.
Side effects
Hypoglycemia (primary risk, carry fast carbs), injection-site edema, jaw pain, carpal tunnel with prolonged use.
What to expect
  • Local anabolic response at the injection site within minutes; systemic effect minimal (rapid IGFBP binding).
  • Muscle fullness/pump lasts 1–2 h.
  • Supply math 1mg → 3 vials (4-wk @ 80 mcg × 7/wk)
Pairs well with
CJC-1295 No DAC + Ipamorelin (GH-axis upstream); BPC-157 / TB-500 (tissue repair); Tesamorelin (visceral fat); Tirzepatide (offsets glucose shifts)
Avoid
Insulin or insulin secretagogues (severe compounded hypoglycemia). Exogenous HGH simultaneously (redundant downstream signaling). Active malignancy. Diabetic retinopathy

Safety & Patient Education

Contraindications
Active malignancy Acute critical illness (post-surgical, ICU): increased mortality reported in trials Severe / proliferative diabetic retinopathy Pregnancy and lactation
Warnings
Intracranial hypertension with somatropin (papilledema, vision changes, headache, nausea, vomiting) Insulin resistance and new-onset T2DM Fluid retention, edema, carpal tunnel Pancreatitis (rare) IGF-1 elevation above age range carries theoretical malignancy risk Hypoglycemia (most important, dose-related), intracranial hypertension, lymphoid hyperplasia (tonsillar)
Drug interactions
Glucocorticoids: blunt GH/IGF-1 response, reassess steroid dose after starting GH Insulin / antidiabetics: GH raises insulin needs; IGF-1 and IGF-1 LR3 cause hypoglycemia, adjust accordingly Levothyroxine: GH lowers free T4, recheck TSH/fT4 quarterly Oral estrogens: blunt GH-stimulated IGF-1, consider transdermal if response is blunted CYP3A4 narrow-TI substrates (cyclosporine, tacrolimus, sirolimus): recheck troughs after starting Anticonvulsants (phenytoin, carbamazepine, phenobarbital): GH may shift seizure threshold; monitor levels
Labs
  • IGF-1 (baseline / Wk 8 / end; you're dosing it directly, so this tracks exposure), Fasting glucose (Wk 0/4/8) Lipid panel (Wk 0/12) Hip/scoliosis exam in pediatrics Out of range?
  • IGF-1 above your age range = too much growth signal → drop the dose.
  • Hypoglycemia is the real acute risk – IGF-1 is insulin-like and can crash blood sugar, so dose with food/carbs and keep fast sugar on hand; shaky, sweaty, or foggy after a dose = treat it, don't wait.
Stop criteria
Severe headache with vision changes (rule out intracranial hypertension) New onset hyperglycemia Persistent edema New-onset hip pain in pediatrics
Patient education
  • Vials must be refrigerated never frozen (somatropin) Rotate injection sites Report headaches with nausea/vision changes immediately Report new joint pain Children: report any limp or hip/knee pain immediately Always have fast-acting carbs available before injection.
  • Do not inject and skip a meal.
References
peptidedosages · DailyMed · PubMed · ClinicalTrials · Drugs.com · Span 2000 · Weissberger 1991